These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
May 22, 2013Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine with Avastin in Treatment of Brain TumorsStudy seeking to enroll 222 patients; largest vaccine trial ever funded by NCI in brain tumors and the largest cancer vaccine study ever conducted in combination with Avastin
Agenus Inc. (NASDAQ: AGEN) today announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200 (Heat Shock Protein Peptide Complex-96 or HSPPC-96) vaccine in combination...
Apr 24, 2013Agenus to Host Conference Call Beginning at 11 a.m. ET Today
Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business...
Apr 18, 2013
Agenus Inc. (Nasdaq:AGEN) will release its first quarter 2013 financial results before the market opens on April 24, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern Time...
Apr 10, 2013Agenus’ Brain Cancer Vaccine Results to be Presented at Plenary Session of the 81st American Association of Neurological Surgeons (AANS) Annual Scientific MeetingFirst Phase 2 Data From Prophage G-100 (HSPPC-96) Newly Diagnosed Glioma Program
Agenus Inc. (NASDAQ: AGEN) reported today that Orin Bloch, MD, Clinical Instructor, Department of Neurological Surgery, University of California San Francisco (UCSF), will present an abstract that...
Mar 14, 2013
Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 25th Annual ROTH Conference, which...